Emily Graves, BS

CONTACT

Lead Sponsor

University of Colorado, Denver

Age

18 - 40 years

Sex

FEMALE

Healthy Volunteers

Yes

•BMI less than or equal to 28kg/m2
•Intact uterus with at least one ovary
•Regular menstrual cycles that occur every 21-35 days
•If patient is postpartum or post-second trimester abortion, 3 menses (2 cycles) must have occurred prior to enrollment
•If patient had a first trimester abortion or pregnancy loss, she must have one spontaneous menses prior to enrollment
•Desires insertion of an etonogestrel contraceptive implant for contraception
•Not currently pregnant or trying to become pregnant
•Willing to abstain from medications and supplements known to induce/inhibit CYP3A4 during the study

•Have a known hypersensitivity or contraindications to etonogestrel.
•Medical conditions that affect liver function (e.g., hepatitis, cirrhosis; assessed via participant self-report)
•Known or suspected current alcohol dependence syndrome or any illicit drug use that may affect the metabolism of the etonogestrel.
•Uncontrolled thyroid disorder.
•Use of long-acting injectable hormonal contraceptive within the past 9 months
•Current use of hormonal oral, patch, intravaginal, or intrauterine contraception